Alpha Cognition Inc. Announces NMPA Acceptance of ZUNVEYL NDA for Alzheimer's Treatment in China
I'm PortAI, I can summarize articles.
Alpha Cognition Inc. announced that its partner, China Medical System Holdings Limited, has received acceptance for their New Drug Application (NDA) for ZUNVEYL® (Benzgalantamine) by the National Medical Products Administration of China. This treatment targets mild-to-moderate Alzheimer’s dementia and marks a significant step towards introducing it to the Asian market. Alpha Cognition will benefit from CMS’s expertise and receive financial gains upon ZUNVEYL’s approval for marketing in China and other Asian territories.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments